Biosyntech Partners With Biomet Inc., a U.S. Biomedical Firm to Develop New Hard Tissue Healing Therapeutics.

Business Editors

LAVAL, QUEBEC--(BUSINESS WIRE)--May 25, 2000

BIOSYNTECH Canada Inc. (OTCBB: BSYI) announces the signing of a collaborative agreement with Biomet Inc (Nasdaq: BMET). Under the agreement, BST-GEL(TM), a family of in situ-gelling polymer solutions developed by BIOSYNTECH, will be studied as a carrier for growth factor and gene delivery to accelerate fresh fracture repair of bones.

"The agreement reached with BIOMET Inc. reaffirms the definitive potential of this innovative approach to therapeutic delivery systems", said Amine Selmani, President and CEO of BIOSYNTECH. "Our proprietary technology is based on natural non-toxic biomaterials that are biodegradable. It can be adapted to many pharmaceutical and biomedical applications and could help to maximize the performance of gene and protein therapies such as those pursued by BIOMET in fracture repair", he added.

BIOSYNTECH's BST-GEL comes as a liquid formulation. As it is injected in the body, it reacts to normal body temperature to form a soluble gel allowing for the retention and controlled release of incorporated therapeutics without affecting their molecular structure

The BST-GEL family of gels is an attractive technology in the delivery of growth factors and genes to accelerate the repair of fresh bone fractures. As an injectable, in situ gelling material, genes and growth factors are retained within the BST-GEL at the fracture site where their action is required.

BIOSYNTECH Canada is a Laval, Quebec-based company that has developed a number of technologies utilizing advanced biomaterials for the delivery of therapeutic agents or biologically active therapeutics. The resulting proprietary technologies offer a range of delivery vehicles with unique properties in a broad range of clinical applications. The components of BIOSYNTECH's biomaterials portfolio are specially adapted for the new generation of therapeutics based on recombinant proteins, genetic material and living cells. BIOSYNTECH has developed four main technology platforms:

I. injectable thermo-sensitive self-forming hydrogels for

therapeutics delivery;

II. solvent- and detergent-free microspheres for therapeutics

delivery;

III. a system for arthroscopic delivery of chondrocytes, using an

adhesive exogenous matrix, for the treatment of cartilage

defects;

IV. a series of calcium-phosphate-based injectable materials, used

for bone-filling and prevention of hip fractures due to

osteoporosis.

V. A medical instrument that provides an objective and sensitive

measure to evaluate cartilage functional properties in the early

and potentially reversible stages of arthritis. The device will

also address an unmet medical need in the unbiased evaluation of

outcome following therapeutic interventions to treat joint and

articular diseases.

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy, including reconstructive and fixation devices, electrical bone growth stimulators, orthopedic support devices, operating room supplies, general surgical instruments, arthroscopy products, spinal implants, bone cements, bone substitutes, craniomaxillofacial implants and dental implants and associated instrumentation. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

This press release contains certain 'forward looking' statements, as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the regulatory authorities having jurisdiction. No regulatory authority has approved or disapproved the content of this release.